4.49
4.42%
+0.19
After Hours:
4.49
Windtree Therapeutics Inc stock is currently priced at $4.49, with a 24-hour trading volume of 8,011.
It has seen a +4.42% increased in the last 24 hours and a +1,019% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $4.39 pivot point. If it approaches the $4.65 resistance level, significant changes may occur.
Previous Close:
$4.30
Open:
$4.2282
24h Volume:
8,011
Market Cap:
$2.29M
Revenue:
-
Net Income/Loss:
$-24.83M
P/E Ratio:
-0.1733
EPS:
-25.91
Net Cash Flow:
$-13.27M
1W Performance:
+9.51%
1M Performance:
+1,019%
6M Performance:
+377.66%
1Y Performance:
+201.34%
Windtree Therapeutics Inc Stock (WINT) Company Profile
Name
Windtree Therapeutics Inc
Sector
Industry
Phone
215 488 9300
Address
2600 Kelly Road, Suite 100, Warrington, PA
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-26-20 | Initiated | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc Stock (WINT) Latest News
Multiple insiders bought Windtree Therapeutics, Inc. (NASDAQ:WINT) stock earlier this year, a positive sign for ... - Yahoo New Zealand News
Yahoo New Zealand News
Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Update - Defense World
Defense World
Windtree Therapeutics (WINT) Stock Forecast and Price Target 2024 - MarketBeat
MarketBeat
Windtree Therapeutics (NASDAQ:WINT) and Sangamo Therapeutics (NASDAQ:SGMO) Head-To-Head Analysis - Defense World
Defense World
Windtree Therapeutics Regains Nasdaq Compliance with Minimum Bid Price Requirement - MyChesCo
MyChesCo
Windtree Therapeutics Regains Nasdaq Compliance with Minimum Bid Price Requirement - MyChesCo
MyChesCo
Windtree Therapeutics Inc Stock (WINT) Financials Data
Windtree Therapeutics Inc (WINT) Net Income 2024
WINT net income (TTM) was -$24.83 million for the quarter ending September 30, 2023, a +41.70% increase year-over-year.
Windtree Therapeutics Inc (WINT) Cash Flow 2024
WINT recorded a free cash flow (TTM) of -$13.27 million for the quarter ending September 30, 2023, a +37.40% increase year-over-year.
Windtree Therapeutics Inc (WINT) Earnings per Share 2024
WINT earnings per share (TTM) was -$20.27 for the quarter ending September 30, 2023, a +71.73% growth year-over-year.
Windtree Therapeutics Inc Stock (WINT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Fraser Craig | President and CEO |
Sep 26 '23 |
Buy |
0.90 |
2,500 |
2,250 |
55,377 |
About Windtree Therapeutics Inc
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
Cap:
|
Volume (24h):